Okami Medical is stepping up commercialization efforts for its LOBO embolization platform, using the SIR2026 conference and new clinical initiatives to build physician adoption. The company is emphasizing LOBO’s imaging advantages, with interventional radiologists on a Backtable podcast citing minimal streak artifact and better visualization of surrounding tissue.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Okami announced first patient enrollment in the ALPHA Registry, a real‑world outcomes study evaluating the LOBO Vascular Occluder in routine clinical practice. The data are expected to support physician confidence and payer assessments over time as the device competes in the vascular occlusion market.
At SIR2026, the company highlighted growing clinical engagement, including work by teams at the University of North Carolina and the University of Chicago that is described as advancing the clinical body of evidence for LOBO. Okami’s presence included a booth, lunch symposium, hands‑on workshop, technology suite demonstrations, and case‑based learning sessions.
The LOBO device is positioned as a next‑generation peripheral embolization solution designed to deliver complete occlusion with improved deliverability and stability in complex procedures. Its compatibility with the SENDERO platform reflects a strategy to offer integrated procedural solutions rather than stand‑alone devices.
Across multiple LinkedIn updates and conference activities, Okami is pursuing a coordinated push that blends clinical evidence generation, specialist education, and marketing. While no new financial, regulatory, or commercial milestones were disclosed, the company’s actions this week appear focused on reinforcing LOBO’s competitive profile and supporting longer‑term reimbursement and adoption.